Trial · NCT01313923
Evaluating Sirolimus to Treat Autoimmune Blistering Dermatosis Pemphigus
NCT01313923, Early phase 1, Terminated, University of California, Irvine; results first posted 2016-03-25
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Evaluating Sirolimus to Treat Autoimmune Blistering Dermatosis Pemphigus. Trials, record NCT01313923. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01313923
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Evaluating Sirolimus to Treat Autoimmune Blistering Dermatosis Pemphigus
- NCT number
- NCT01313923
- Status
- Terminated
- Phases
- Early phase 1
- Enrollment
- 3 participants, actual
- Lead sponsor
- University of California, Irvine
- Conditions
- Pemphigus
- Interventions
- Sirolimus (formerly known as Rapamycin)
- First posted
- 2011-03-14
- Last updated
- 2017-06-09
- Results first posted
- 2016-03-25
- Limitations and caveats
- No results as study has been terminated early by the investigator.
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Improvement of ABSIS Score While Reducing Steroid Dosage | Expected time line 24 months | Measurement of disease severity will be quantified using ABSIS (Autoimmune Bullous Skin Disorder Intensity Score). Improvement in disease control is quantified by the maintenance or improvement of ABSIS score while reducing steroid dosage. No results as study has been terminated early by the investigator. |
| Secondary | Statistical Measures | Study early termination by investigator - no participant completed any visits of the study - no measurements taken | The statistical goal is to observe "success," an improvement in disease control while up-titrating sirolimus dosage. As there will be no control group, the subject or progress at the end of the study will be compared to their baseline at the beginning of the study. The subject and disease severity at the beginning of the study will be compared to the disease severity at each visit and be correlated with the dosage of sirolimus and corticosteroid. However, since no patient completed the study, the outcome and any data collected was not assessed. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Improvement of ABSIS Score While Reducing Steroid Dosage | Expected time line 24 months | This outcome was not assessed because no participant completed any visits of the study | ||
| SECONDARY | Statistical Measures | Study early termination by investigator - no participant completed any visits of the study - no measurements taken |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Sirolimus | 3 | |
| Overall Study | COMPLETED | Sirolimus | 0 | |
| Overall Study | NOT COMPLETED | Sirolimus | 3 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Sirolimus (Formerly Known as Rapamycin) | ||
| Total, other adverse events | Sirolimus (Formerly Known as Rapamycin) | 0 | 0 |
| Total, serious adverse events | Sirolimus (Formerly Known as Rapamycin) | 0 | 0 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01313923
GET https://conductscience.org/api/trials/v1/NCT01313923/registered